Fig. 1From: Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA RegistryPatient attrition. *Over 80% of the patients in the JAKi group were on tofacitinib. ADA, adalimumab; ETN, etanercept; JAKi, Janus kinase inhibitorBack to article page